Introduction {#s1}
============

Chloroquine and hydroxychloroquine are closely related 4-aminoquinoline drugs used for the treatment of malaria, amoebiasis and rheumatological conditions ([@bib48]). Until the late 1990s chloroquine was the drug of choice for the treatment of malaria. Hundreds of tons corresponding to over 200 million doses were consumed annually. Since then its use has declined because of widespread resistance in *Plasmodium falciparum*. Today there is greater use of hydroxychloroquine in rheumatoid arthritis and discoid and systemic lupus erythematosus. Chloroquine and hydroxychloroquine are antivirals with a broad range of activities (including flaviviruses, retroviruses, and coronaviruses) ([@bib38]; [@bib24]; [@bib45]; [@bib51]; [@bib29]). Their antiviral activity against SARS-CoV2 is expected to be weak as predicted unbound concentrations of hydroxychloroquine and chloroquine in vivo with currently recommended doses are lower than the half-maximal effect concentrations reported in Vero cell cultures ([@bib47]). This has motivated trialling of higher loading and maintenance doses than usually given in malaria or hepatic amoebiasis ([@bib48]; [@bib12]). As of the 11th June 2020, 77 interventional clinical trials evaluating these drugs in both the prevention and treatment of COVID-19 were registered and recruiting participants on [ClinicalTrials.gov](https://clinicaltrials.gov/). [Figure 1](#fig1){ref-type="fig"} shows a scatter plot of the duration versus total dose in base equivalent for the 55 trials using chloroquine or hydroxychloroquine for the treatment of hospitalised COVID-19 patients for which exact dosing could be extracted. The doses and durations varied greatly. The high doses used by some trials have caused concern over the potential for cardiovascular toxicity. Nevertheless, despite the lack of any convincing evidence of clinical benefit, these drugs are now being used extensively in COVID-19 prevention and treatment across the world. Sadly, patients who need hydroxychloroquine or chloroquine for the treatment of malaria and rheumatological conditions are often having difficulty obtaining them ([@bib39]).

![The total chloroquine or hydroxychloroquine dose (in grams) and duration of 55 COVID-19 treatment trials currently recruiting participants, extracted from [ClinicalTrials.gov](https://clinicaltrials.gov/) on the 11th June 2020.\
The black open square boxes show the four 'flat' dosing chloroquine regimens simulated in this paper. Note that many trials give the same dose regimen so there are fewer than 55 unique points on the graph. Some multi-country trials such as SOLIDARITY use both hydroxychloroquine or chloroquine depending on the countries included. As the majority of countries worldwide use hydroxychloroquine we have colored these trials in red. The extracted data can be found in the supplementary materials.\
Figure 1---source data 1.Extracted meta-data from 55 trials registered on [Clinicaltrials.gov](https://clinicaltrials.gov/) using chloroquine or hydroxychloroquine for the treatment of COVID-19.](elife-58631-fig1){#fig1}

Borba et al. reported results from a randomised trial in Brazil of two dose regimens of chloroquine in COVID-19 treatment (*CloroCovid-19* study, [ClinicalTrials.gov](https://clinicaltrials.gov/) NCT04323527) ([@bib2]). The trial was stopped early after recruiting only 81 patients because of cardiac toxicity and greater mortality in the higher dose group; two of 41 patients given the higher dose regimen developed ventricular tachycardia before death and 7 of 37 patients in this group developed electrocardiograph QTcF intervals over 500 msec compared with 4 of 36 in the lower dose group. The higher dose regimen, comprising 600 mg base chloroquine administered twice daily for ten days, is substantially higher than recommended in malaria or rheumatological conditions ([@bib48]) and represents the standard malaria loading dose repeated 19 times at 12 hr intervals.

Chloroquine is dangerous in overdose and has been used extensively for suicide. High concentrations of chloroquine cause hypotension, arrhythmias, coma, acute respiratory distress syndrome (ARDS), and fatal cardiac arrest ([@bib35]; [@bib10]; [@bib11]; [@bib28]). In Zimbabwe the mortality of chloroquine in overdose was approximately six times higher than for other drugs ([@bib1]). In France in the early 1980s there was a suicide epidemic ([@bib35]; [@bib10]; [@bib11]; [@bib28] ) following the publication of a book entitled *Suicide: mode d'emploi* (Suicide: a how-to guide) ([@bib16]). This unfortunate experience allowed characterization of the factors associated with death from chloroquine overdose. Outcome in chloroquine self-poisoning depends on the dose ingested, the delay in reaching hospital and the quality of intensive care support. Using the blood concentration measurements taken from self-poisoning patients managed by experienced intensivists in the French National referral centre allowed development of a pharmacokinetic-pharmacodynamic model to estimate the relationship between chloroquine dosing and a fatal outcome. A pooled analysis using electrocardiograph QRS interval data from healthy volunteers ([@bib34]) and from the French self-poisoning cohorts helped characterise the contribution of QRS prolongation to the recorded QT prolongation. These models were used to estimate the safety of the main treatment regimens currently used in COVID-19 clinical trials and of the standard malaria treatment regimen for comparison.

Results {#s2}
=======

Predicting mortality in self-poisoning from peak chloroquine concentrations {#s2-1}
---------------------------------------------------------------------------

We pooled individual patient whole blood chloroquine + desethylchloroquine concentrations and outcomes from three large prospectively studied hospital self-poisoning cohorts (n = 302, [Figure 2](#fig2){ref-type="fig"}, top panel) ([@bib35]; [@bib10]; [@bib11]; [@bib28]). All the patients included in this analysis were treated in the same hospital in Paris and all had whole blood concentrations measured on admission. The overall mortality was 11% (33 of 302). Of the patients with multiple concentration measurements ($n = 173$), 61 (35%) reached their peak whole blood chloroquine concentrations after admission. The distribution of differences on the log scale between admission whole blood concentrations and peak concentrations in patients who peaked after hospital admission was used to estimate a correction term for all other patients. Bayesian logistic regression was used to estimate the relationship between mortality and inferred whole blood peak chloroquine concentrations ([Figure 2](#fig2){ref-type="fig"}, bottom panel) specifically adjusted for the desethyl metabolite levels and for the non-observed peak concentrations in 241 (80%) of the patients. The model also adjusted for differences in treatment received between cohorts. The whole blood chloroquine concentration associated with 1% mortality was 13.5 µmol/L (95% C.I. 10.1 to 17.7). 1% is the lowest mortality for which a reliable estimate can be derived from these data. The 1% threshold value was then used to evaluate the risk of fatal toxicity in chloroquine treatment regimens under evaluation in COVID-19.

![Pharmacokinetic-pharmacodynamic model of chloroquine induced mortality.\
Top: pooled whole blood chloroquine + desethylchloroquine concentrations from admission samples in 302 prospectively studied self-poisoning patients ([@bib35]; [@bib10]; [@bib11]; [@bib28]). The data are shown as overlapping histograms for survivors (yellow, $n = 269$) and fatal cases (red, $n = 33$). Bottom: Bayesian posterior distribution over the concentration-response curve (mean and 95% credible interval) describing the relationship between inferred whole blood chloroquine peak concentrations (after adjustment for the desethyl metabolite) and death, with the chloroquine concentration shown on the log~10~ scale. The vertical lines show the upper 99 percentiles of the predicted C~max~ distribution in a 70 kg adult under the whole blood pharmacokinetic model for the six adult dose regimens considered (pink: 10 day regimen with 12 hourly maintenance dose of 600 mg (base); brown: 10 day regimen with 12 hourly maintenance dose of 310 mg (base); green: 7 day regimen with 12 hourly maintenance dose of 310 mg (base) ; grey: malaria treatment regimen). The vertical light pink shaded area shows the posterior credible interval over the concentrations associated with 1% mortality. The equivalent output with the plasma pharmacokinetic model is shown in Appendix 4.](elife-58631-fig2){#fig2}

Predicting mortality from peak blood concentrations in COVID-19 treatment regimens {#s2-2}
----------------------------------------------------------------------------------

We used two pharmacokinetic models to predict peak chloroquine concentrations for six chloroquine regimens. Five of the simulated regimens are potential COVID treatment regimens, and one is the standard malaria treatment regimen. A very wide range of chloroquine and hydroxychloroquine regimens are currently in use for the treatment of COVID-19 ([Figure 1](#fig1){ref-type="fig"}). The COVID-19 regimens we simulated correspond to the highest chloroquine treatment regimen (in terms of total dose) registered at [ClinicalTrials.gov](https://clinicaltrials.gov/) ([@bib2]); the regimen given in the World Health Organization SOLIDARITY trial (NCT04330690); a lower 7 day adaptation of the SOLIDARITY regimen; and weight-optimised equivalent regimens.

The pharmacokinetic model estimated from whole blood concentrations ([@bib20]) predicted a slightly wider range of values for maximum chloroquine concentrations (C~max~) than the plasma-based model (Appendix 3 shows the predicted C~max~ distributions for both models in a 70 kg adult). Assuming a whole blood to plasma concentration ratio of 4, the whole blood-based model and the plasma-based model predicted approximately identical median C~max~ values. Thus, the whole blood pharmacokinetic model provides higher estimates for fatal toxicity because it predicts a larger variance for the C~max~ distribution and hence more extreme outliers. As a sensitivity analysis, the equivalent outputs for the plasma-based model are shown in Appendix 4.

Based on the whole blood model, the median C~max~ following a chloroquine dose of 600 mg base equivalent given twice daily for ten days to a 70 kg adult is 10.7 µmol/L ([Figure 3](#fig3){ref-type="fig"}, panel A). This is more than three times higher than the median C~max~ for the chloroquine malaria treatment regimen at the same body weight. Approximately 60% of 70 kg adults continuing to receive the twice daily 600 mg dose have blood concentrations which rise into the 'danger zone' defined as whole blood concentrations above 10 µmol/L. In comparison, only two in a thousand 70 kg adults receiving the twice daily 310 mg base maintenance dose (as given in the SOLIDARITY and RECOVERY trials) for ten days would reach concentrations above 10 µmol/L (approximately the lower bound for the 1% mortality threshold). Taking into account the uncertainty around this threshold value, the model estimates that fewer than one per thousand receiving the twice daily 310 mg dose would have peak concentrations above the 1% mortality threshold ([Figure 3](#fig3){ref-type="fig"}, panel B). Clearly body weight is an important determinant of exposure if doses are not adjusted for weight, as is common with oral administration (chloroquine and hydroxychloroquine tablets usually contain 155 mg base). At most, two in a thousand 40 kg adults receiving the 3 day malaria treatment regimen without weight adjustment (i.e. an unusually high mg/kg dose) are predicted to reach peak concentrations above 10 µmol/L.

![The predicted risk of potentially fatal chloroquine toxicity across the six regimens simulated under the whole blood pharmacokinetic model.\
Panel A shows the simulated distribution of C~max~ values in a 70 kg adult for the five COVID-19 treatment regimens under evaluation and the standard malaria treatment regimen. The vertical light pink shaded area shows the 95% credible interval for the 1% mortality threshold concentration. Panel B shows the probability that an individual will cross the 1% mortality threshold value as a function of body weight for the different chloroquine regimens (log~10~ scale on the y-axis). Panel C shows the predicted mortality per thousand for the six chloroquine regimens as a function of body weight. The equivalent output using the plasma pharmacokinetic model is given in Appendix 4.](elife-58631-fig3){#fig3}

Coupling the pharmacokinetic model with the pharmacodynamic model, we estimated the expected weight-dependent fatality ratios for the five COVID-19 chloroquine treatment regimens, truncating the concentration-fatality curve at the 1% mortality threshold (only taking into account concentrations going above this threshold). Administering 600 mg base equivalent of chloroquine phosphate twice daily for ten days as in the *CloroCovid-19* trial is predicted to result in absolute mean fatality ratios ranging between 0.05% (90 kg, 95% credible interval (C.I.), 0% to 0.3%) and 3.5% (40 kg, 95% C.I. 1.0% to 8.0%), [Figure 3](#fig3){ref-type="fig"}, panel C. In comparison, only the flat dosing regimens are predicted to result in fatality ratios greater than one per thousand, and then only for weights less than 55 kg: for a 40 kg adult the 10 day SOLIDARITY regimen could result in 0.2% mortality (95% CI, 0 to 0.8). The 10 day flat regimen (without a loading dose) of 500 mg chloroquine phosphate salt (310 mg base equivalent) twice daily was recommended by the Health Commission of Guangdong Province for adults weighing more than 50 kg ([@bib32]). This is not predicted to incur a significant risk of cardiotoxicity. Overall the model predictions support this body weight threshold for dose reduction.

Concentration-dependent electrocardiograph QRS prolongation {#s2-3}
-----------------------------------------------------------

We pooled individual electrocardiograph QRS intervals and chloroquine concentration data from 16 healthy volunteers ([@bib34], for each individual the QRS interval was measured twice at rest and 12 times in presence of detectable plasma chloroquine concentrations after a single 620 mg base oral dose of chloroquine phosphate), and 290 self-poisoning patients (no QRS data from Riou et al., and one missing QRS measurement from the Clemessy cohort), [Figure 4](#fig4){ref-type="fig"}. We fitted a hierarchical Bayesian Emax sigmoid regression model to the paired concentration-QRS data and the steady state QRS data (healthy volunteers only), a total of $n = 514$ datapoints. A whole blood chloroquine concentration of 3 µmol/L (usually observed in malaria treatment) is associated with a slight QRS prolongation of 6.7 msec (95% credible interval, 5.5--7.8). Clinically significant intraventricular conduction delay (QRS prolongation), resulting in durations greater than 150 msec, was strongly associated with observed chloroquine concentrations above 10 µmol/L. In self-poisoning, 1 out of 108 patients with admission whole blood concentrations less than 10 µmol/L had a QRS interval longer than 150 msec (this accounts for the bias term estimated in the Clemessy cohort). In comparison, QRS durations longer than 150 msec were recorded in 36 out of 182 (20%) of the patients with whole blood concentrations greater than 10 µmol/L. In self-poisoning patients, QRS duration was an independent predictor of death (adjusted odds ratio for death of 1.3 for each 10 msec increase in QRS, $p < 10^{- 5}$).

![Electrocardiograph QRS interval duration as a function of whole blood chloroquine concentrations.\
The data shown in the scatter plot are from 16 healthy volunteers who took a single 620 mg base oral dose (green circles, 192 paired concentration-QRS data-points, plasma concentrations were multiplied by 4) and 290 chloroquine self-poisoning patients (red and blue, hospital admission concentrations). Random normal jitter (standard deviation of 1 ms) was added to the Clemessy cohort self-poisoning QRS values for improved visualization. Survivors are shown as circles and fatal cases as triangles. The self-poisoning electrocardiograph QRS values from the Clemessy series ([@bib10]; [@bib11]) were read manually and are adjusted for a bias term (see Materials and methods, non-adjusted data are shown in Appendix 5). The grey line (grey area) shows the estimated median QRS duration (range) in the 16 healthy volunteers in absence of measurable drug. The thick black line shows the mean posterior Emax sigmoid regression model, fitted to the pooled data. The dashed green and blue lines show the posterior predictive distribution under the error distributions for the healthy volunteers and Megarbane self-poisoning cohort (smaller measurement error than in the Clemessy cohort), respectively (see Materials and methods for the full specification of the model). Note that the Emax regression model does not account for concentration-dependent heteroskedasticity but only inter-individual variation for healthy volunteers and inter-study variation (differences in measurement).](elife-58631-fig4){#fig4}

Discussion {#s3}
==========

Chloroquine is dangerous in overdose. The risk of death is proportional to drug exposure. Mortality rises steeply at whole blood chloroquine concentrations above 10 µmol/L. This corresponds very approximately to a plasma concentration of 3 µmol/L, and a combined chloroquine and desethylchloroquine concentration (as in a spectrophotometric assay) of 14 µmol/L. Importantly the electrocardiograph is a valuable indicator of toxicity as potentially lethal levels are associated with significant QRS complex widening. A QRS duration of less than 100 msec makes lethal toxicity very unlikely. When using high-dose treatments weight adjusted dosing is important to avoid toxicity.

Implications for COVID treatment regimens {#s3-1}
-----------------------------------------

Chloroquine and hydroxychloroquine are already being used extensively, and often in high doses, to prevent and treat COVID-19 despite the current lack of convincing evidence of benefit. Use of these drugs has become extremely politicised. The first large randomised trial in the treatment of hospitalised patients has just reported (RECOVERY, NCT04381936: press release only at the time of writing, results are not yet peer reviewed). This result strongly suggests that hydroxychloroquine (and also lopinavir-ritonavir) does not benefit hospitalised patients. The preliminary results of the same trial show that dexamethasone has a major life saving benefit in patients receiving oxygen or being ventilated. This supports a paradigm of early benefit from an effective antiviral and late benefit from an anti-inflammatory drug. Thus there remains a potential role for chloroquine and hydroxychloroquine in prevention and early treatment. However the prevention trials will not report for many months hence. Confusion over the risks associated with chloroquine and hydroxychloroquine has been compounded by a recent high profile claim of increased mortality and high rates of ventricular arrhythmia in a very large observational data set. This data set was almost certainly fabricated (and the paper was subsequently retracted, [@bib30]). Unfortunately over-reactions by some regulatory agencies, unjustified extrapolations of risk from QT measurements, failure to distinguish the effects of the drugs given alone from the combination with azithromycin, and misunderstanding of their clinical pharmacology have conspired to reduce confidence in these drugs and jeopardise the very trials needed to characterise risks and benefits in the prevention and treatment of COVID-19 ([@bib47]). Chloroquine and hydroxychloroquine have unusual pharmacokinetic properties with very large total apparent volumes of distribution (V~*d*~) (chloroquine \> hydroxychloroquine) and very slow terminal elimination rates (terminal half-lives exceed one month) which cannot be measured accurately. Thus, distribution processes, rather than elimination, govern the blood concentration profiles in the first days following the start of treatment. Large single doses (as in self-poisoning) are very dangerous because they result in high blood concentrations as the drugs distribute out from a central 'compartment' that is hundreds of times smaller than the total apparent V~*d*~ (compartmental modeling of chloroquine pharmacokinetics provides only an approximation of the distribution processes). These high concentrations can cause potentially lethal cardiovascular and nervous system toxicity. Chloroquine affects cardiac muscle depolarization, repolarization and contractility and also causes vasodilation. There is concentration-dependent electrocardiograph QRS widening and JT prolongation ([@bib10]; [@bib11]) which both contribute to QT prolongation. Death usually results from refractory hypotension or ventricular fibrillation. Self-poisoning with chloroquine has provided an unfortunate opportunity to correlate drug exposure with the risk of iatrogenic death.

As chloroquine has relatively weak antiviral activity, if there is benefit in COVID-19 infections, it is likely to require high drug exposures. At the beginning of the COVID-19 pandemic a large number of investigators started studies of chloroquine and hydroxychloroquine. The toxicity thresholds were not well defined and a range of dose regimens were evaluated in the hope that benefits would exceed risks ([Figure 1](#fig1){ref-type="fig"}). The high dose chloroquine regimen evaluated by Borba et al. in Brazil did encounter cardiac toxicity. This study referenced the recommendations by the Health Commission of Guangdong Province based on the Chinese experience, but there may have been confusion between salt and base weights ([@bib32]). Whereas the Chinese authorities recommended 500 mg *salt* twice daily (two tablets of chloroquine phosphate 250 mg, comprising 155 mg base each), the Brazil study ([@bib2]) gave doses in base equivalent (600 mg base 12 hourly) which were consequently much higher. Importantly the patients in the Brazilian study also received azithromycin (which also prolongs the QT interval, and this may well have contributed to ventricular arrhythmias, [@bib36]; [@bib23]). This pharmacometric analysis of the French self-poisoning cohorts provides an evidence-based toxicity threshold. It suggests that a continued regimen of 600 mg twice daily can be directly lethal. Lower dose regimens such as those evaluated in the large RECOVERY and SOLIDARITY trials, and the original Guangdong recommendations, are predicted to be safe. Doses of chloroquine alone, resulting in peak concentrations greater than 10 µmol/L are associated with more than 1% risk of fatal toxicity.

Limitations {#s3-2}
-----------

There are several limitations to this study. It is a retrospective individual patient data analysis. In the suicide attempts, other drugs or alcohol were often taken as well, although none with the acute lethal toxicity of chloroquine. Patients were managed by experienced intensivists on intensive care units where there was close clinical and laboratory monitoring. Mortality might be higher in less well supported settings, or in overloaded hospitals in high-income settings. The age range in self-poisoning is also younger than in the majority of more seriously ill COVID-19 patients. The spectrophotometric assay method does not separate chloroquine from its desethylated metabolite, and is relatively insensitive. Desethychloroquine has generally similar biological properties, and the assay performs well at the high concentrations of relevance to this study. We corrected for the presence of the metabolite under the Bayesian model, but this correction increases uncertainty around the threshold concentration associated with 1% mortality. The predictions of absolute mortality under the regimens simulated in this work are sensitive to the parameterization of the pharmacokinetic model. C~max~ is not observed directly but is an output model-based quantity estimated from data. There are no large population pharmacokinetic studies to verify the precision of the C~max~ predictions, especially for the critical upper tails of the distribution.

The pharmacokinetic-pharmacodynamic model developed here was based on the largest prospective series of chloroquine self-poisonings studied in a single referral centre. However, it was not possible to apply a standard pharmacokinetic model to the observed data in order to estimate the individual C~max~ values. Mainly because of vomiting, admission blood concentrations only weakly correlate with the self-administered chloroquine doses ([@bib10]). Our model was based on a majority of admission whole blood concentrations. The data from patients whose peak drug concentrations occurred after hospital admission were used to approximate the difference between unobserved peak concentrations and admission concentrations in the remaining patients. Overall, the admission concentrations were estimated to be approximately 5% lower on average than the peak concentrations. This corresponds to prior expectations: the mean interval to hospitalization for this large self-poisoning cohort was 4.5 hr compared with an average time to peak concentration after oral administration of 3 hr (range 1--6 hr) ([@bib34]). The outcome of chloroquine poisoning depends on the quality of intensive care support. Over the period of this retrospective review, in addition to the experience gained in this one referral centre, there were significant improvements in intensive care which would have improved the prognosis for a given drug exposure. Sustaining the cardiorespiratory system mechanically with extracorporeal membrane oxygenation (ECMO) ([@bib27]) while toxic concentrations decline as the drug distributes may have made a significant contribution to improved survival.

One death occurred in a 32-year-old female who took 2.8 grams of chloroquine phosphate and whose admission whole blood chloroquine+desethychloroquine concentration was 9.8 µmol/L. She had homozygous sickle cell disease and an admission hemoglobin of 7.9 g/dL. She was treated with ECMO and blood transfusion. She died from hemorrhagic ARDS even though her cardiac function improved. It is likely that acute and chronic complications of sickle cell disease contributed significantly to the fatal outcome associated with chloroquine overdose.

Our analysis does not make specific predictions for the toxicity of hydroxychloroquine regimens currently in use for the treatment of COVID-19. The majority of clinical trials are evaluating hydroxychloroquine, not chloroquine, as it is considered to be slightly safer and is more widely available in the countries where most trials are being conducted. Although hydroxychloroquine has a wider therapeutic margin in experimental animals ([@bib26]), it has generally similar pharmacokinetic properties and, although there are limited data, the pharmacodynamic properties are also generally similar to chloroquine. The clinical features of hydroxychloroquine and chloroquine in overdose are also similar. But unlike chloroquine, there are no large cohorts of hydroxychloroquine self-poisoning on which to define toxicity thresholds. Thus, given available toxicity data, it is very unlikely that equivalent hydroxychloroquine concentrations to chloroquine are more dangerous, but rather that the safety margins are wider. Our systematic review of regimens currently being used for the treatment of COVID identified one trial currently recruiting patients (PATCH, NCT04329923) which is administering very high doses of hydroxychloroquine ([Figure 1](#fig1){ref-type="fig"}). This dose of 1200 mg/day (930 mg base/day) for 14 days would be predicted to have a significant risk of incurring dangerous toxicity were hydroxychloroquine and chloroquine to have molar equivalent toxicities. However the majority of regimens currently being tested for COVID-19 treatment are predicted to be safe.

Electrocardiograph QT concerns limit COVID-19 studies {#s3-3}
-----------------------------------------------------

Concerns over QT prolongation dominate the reasons for not endorsing or not participating in COVID 19 trials with chloroquine or hydroxychloroquine. Many recent articles on COVID-19 therapeutics caution against the risks of iatrogenic 'torsade de pointes' (TdP) with these drugs ([@bib33]; [@bib31]; [@bib6]; [@bib18]; [@bib15]; [@bib43]; [@bib21]; [@bib37]). Both drugs do cause significant QT prolongation and, whilst they block several different cation channels affecting myocardial depolarization (resulting in QRS prolongation) and repolarization (resulting in JT prolongation), the multichannel block is considered unbalanced, and both drugs are regarded as 'torsadagenic' ([@bib44]). Many of the recent reports rediscovering this well known effect omit description of the contribution of QRS widening to QT prolongation (and thereby overestimate JT prolongation).

Approximately 350 tons of hydroxychloroquine are manufactured each year, almost all of which is used for rheumatological conditions, so millions are receiving long term regimens. Many of these patients have systemic lupus erythematosus which is commonly associated with myocarditis, QT prolongation, and a high prevalence of arrhythmias ([@bib14]; [@bib3]). Reviews and authoritative websites all state that hydroxychloroquine causes TdP. Yet, despite this enormous use, in a systematic review of the literature we can find only a single reported case of TdP outside of COVID-19 treatment. This was in a 67-year-old Taiwanese female with systemic lupus erythematosus, cirrhosis and a previous myocardial infarct who was receiving hydroxychloroquine ([@bib7]). The patient survived. The WHO pharmacovigilance database (VigiBase) contains reports of 83 episodes of ventricular tachycardia associated with hydroxychloroquine over a 52 year period of which seven were fatal (this does not distinguish acute toxicity from the well described chronic toxic cardiomyopathy associated with use over many years). Overall, in systemic lupus erythematosus, patients receiving chloroquine have fewer arrhythmias than those on other medicines ([@bib41]; [@bib49]). In a very large retrospective observational study of 956,374 patients with rheumatoid arthritis starting hydroxychloroquine, there were significantly less arrhythmias in the first month of treatment with hydroxychloroquine compared to patients (N = 310,350) started on sulphasalazine ([@bib23]). This reflects the under-recognised anti-arrhythmic effects of these drugs ([@bib19]). In COVID-19 treatment there have been two reports so far of TdP. An 84-year-old Israeli woman with metastatic breast cancer who was taking bisoprolol, letrozole and memantine and received chloroquine treatment ([@bib40]), and a 68-year-old American male given hydroxychloroquine and azithromycin ([@bib8]). Neither of these episodes were fatal. In Europe and the USA, where chloroquine and hydroxychloroquine are allowed for compassionate use, there have been more than 300,000 deaths from COVID-19. The apparently low rates of reported ventricular arrhythmia are surprising given that evidence of myocarditis in lethal COVID-19 is common ([@bib22]; [@bib25]). The two largest randomised trials in hospitalised COVID-19 patients (RECOVERY and SOLIDARITY) have together randomised 2473 patients to receive hydroxychloroquine. They do not show increased mortality at the times expected if hydroxychloroquine was causing lethal cardiovascular toxicity (i.e. on the first and last days of treatment). Except in deliberate self-poisoning TdP has not been reported with chloroquine either, despite billions of malaria treatments and extensive use in rheumatological conditions and hepatic amoebiasis for over 70 years. Thus it appears that the individual risk over the short term with currently used doses is very low. Subjects with pre-existing long QT intervals, electrolyte imbalance, concomitant QT prolonging medications (notably azithromycin in COVID-19) and structural heart disease are likely to be at greater individual risk. The very low risks of drug induced arrhythmia over the short term should be distinguished clearly from long term cumulative cardiotoxicity. The main cardiac concerns with long term usage of chloroquine and hydroxychloroquine are conduction defects and cardiomyopathy ([@bib42]).

In summary, despite causing significant QT prolongation, there is no evidence that the risks of TdP and sudden death with chloroquine and hydroxychloroquine given alone at currently recommended doses over the short term are increased above those of the background population. Restricting the evaluation of these drugs in COVID-19 for this specific concern therefore seems unwarranted. In assessing the potential toxicity of these drugs QRS widening correlates with severity.

Risk-benefit assessment in the treatment of COVID-19 {#s3-4}
----------------------------------------------------

COVID-19 ranges from very mild illness to severe disease necessitating intensive care. Case fatality ratios are highly age dependent ([@bib50]). The potential toxicity of a treatment regimen has to be balanced against the severity of illness. If chloroquine is to benefit patients with COVID-19, it is likely to require high exposures. Understanding the concentration-dependent toxicity of chloroquine is essential in assessing the risk-benefit trade-off in COVID-19 clinical trials. This is evidence-based whereas the presumption of risk from lethal TdP derived from the measurement of electrocardiograph QT prolongation (which dominates the current literature) is not. From a clinical perspective, there are several practical implications of these observations in self-poisoning. If high doses of chloroquine or hydroxychloroquine are being given to hospitalised patients and blood concentrations cannot be measured rapidly (which is the usual situation), then electrocardiographic monitoring is informative. QRS interval widening can be used as an indicator of toxicity. If the QRS interval is less than 100 msec, then serious cardiovascular toxicity is very unlikely. JT interval prolongation is expected, and should be monitored too, but it is often harder to assess (as the end of T wave definition is often unclear in chloroquine toxicity). Hypokalemia is an important manifestation of chloroquine poisoning and a contributor to tachyarrhythmias ([@bib10]). With high dose regimens plasma potassium concentrations should be maintained over 4.0 mmol/L and plasma magnesium concentrations over 0.8 mmol/L. Overall treatment regimens for hospitalised COVID-19 patients which result in whole blood chloroquine concentrations below 10 µmol/L for more than 95% of patients have an acceptable safety margin.

Materials and methods {#s4}
=====================

Patient data {#s4-1}
------------

The largest prospectively studied cohorts of self-poisoning with chloroquine have all been assembled by the national clinical toxicology unit in Paris, France (Réanimation Médicale et Toxicologique, Hôpital Lariboisière). The clinical and laboratory characteristics of these cohorts have been published in detail previously ([@bib35]; [@bib10]; [@bib11]; [@bib28]). The extensive experience gathered in this clinical toxicology unit established the standard of care for chloroquine poisoning, including mechanical ventilation, appropriate sedation and optimum use of inotropes and vasopressors. Pre-hospital care was provided by emergency physicians in mobile intensive care units. These units could perform 12-lead electrocardiograms as well as advanced life support. Whole blood chloroquine concentrations were measured on admission and at varying times subsequently. The whole blood chloroquine concentrations following self-poisoning were determined using ultraviolet spectrophotometry at a wavelength of 343 nm. This analytical method does not differentiate between chloroquine and the biologically active desethyl metabolite.

Original drug concentration measurements, electrocardiograph QRS durations and outcome data were available for all prospectively studied patients from 1987 to 1994 ([@bib10]; [@bib11]) and a later cohort studied from 2003 to 2007 ([@bib28]). Patients were included in the prospective studies, if there was a history of attempted suicide and chloroquine was present in the admission whole blood sample. For all patients studied prospectively between February 1987 and January 1992 ($n = 167$, [@bib11]) multiple whole blood chloroquine measurements were taken during the first 48 hr of hospital stay. The number and timing of samples varied between cases. Original data were not available for [@bib35] so concentrations and outcomes were extracted from graphs in the publication (Figure 3 in [@bib35]). Whole blood chloroquine concentrations and outcome could be determined approximately for all 102 patients. Data were extracted using the web version of WebPlotDigitizer (<https://automeris.io/WebPlotDigitizer/>).

Electrocardiograph QRS durations were manually read for all patients in [@bib10]; [@bib11]. Automated and manual readings were used for patients in [@bib28]. We did not have reliable QT interval measurements for the chloroquine self-poisoning patients. It is often impossible to determine accurately the end of the T wave in the presence of the extremely high chloroquine concentrations observed in self-poisoning (in the 10--100 µmol/L range). Several case reports of massive chloroquine overdose show illustrative electrocardiograms in which the QT interval is difficult or impossible to measure accurately, e.g. [@bib17]; [@bib13]. An ECG typical of chloroquine self-poisoning, with substantial QRS widening and moderate JT prolongation, is shown in Appendix 6.

To characterise the relationship between chloroquine concentrations and QRS prolongation, we used plasma chloroquine concentration measurements (from solid phase extraction and high performance liquid chromatography with UV detection) and electrocardiograph QRS interval measurements from 16 healthy volunteers who took single 620 mg doses of chloroquine base orally ([@bib34], we note that in the original publication it states that this was a 600 mg single dose, but this is a typographic error). The healthy volunteer QRS data consisted of 32 measurements in the absence of drug (two separate occasions for each volunteer) and 192 (12 per volunteer) paired chloroquine concentration-QRS measurements.

Literature review {#s4-2}
-----------------

We conducted a literature review of all published case reports and hospital cohorts on chloroquine poisoning. We extracted data from 12 case reports (13 patients) in which whole blood or plasma chloroquine concentrations were reported. We analyzed only case reports in which blood or plasma concentrations were obtained ante-mortem as the post mortem redistribution of chloroquine from tissues to the blood is unknown. However, the data from the case reports exhibited significant bias towards patients with high concentrations who survived (i.e. unusual cases) so these were excluded from the final model. To review reports of Torsade de Pointes associated with chloroquine or hydroxychloroquine PubMed and EmBase were searched using the terms 'HYDROXYCHLOROQUINE' or 'CHLOROQUINE' AND either 'TORSADE', 'ARRHYTHMIA', 'SUDDEN DEATH' or 'CARDIAC ARREST'.

We searched [ClinicalTrials.gov](https://clinicaltrials.gov/) on the 11th of June 2020 (<https://clinicaltrials.gov/ct2/home>) for clinical trials using hydroxychloroquine and chloroquine for the treatment of COVID-19 (search terms: condition = COVID; other terms = hospital; intervention = hydroxychloroquine OR chloroquine; status = recruiting). This gave 77 results. After filtering out prevention studies, we could determine the total dose in base equivalent for 55 treatment studies (these are presented in a [Figure 1---source data 1](#fig1sdata1){ref-type="supplementary-material"}).

Pharmacokinetic modeling {#s4-3}
------------------------

Chloroquine has complex pharmacokinetic properties characterised by a very large volume of distribution and a terminal elimination half-life of over a month. Both of these parameters are difficult to estimate accurately from pharmacokinetic data ([@bib47]). Whole blood (the currently preferred matrix) concentrations are significantly higher than plasma concentrations because of binding to red blood cells, leukocytes and platelets. Two models were used for simulation in NONMEM (v.7.4.3, Icon Development Solution, Ellicott City, MD; the NONMEM simulation code is available online; see github repository link below). The first was a published two-compartment disposition model with a transit compartment absorption model using whole blood measurements from adult vivax malaria patients treated with a standard 25 mg base/kg regimen over three days ([@bib20]) ($n = 75$, with over 1000 concentration measurements). Allometric scaling of body weight, with the exponent fixed to 0.75 for clearance parameters and one for volume parameters, was added to the published model to predict concentrations at different body weights. Although a two compartment model underestimates the terminal elimination phase, this has little effect on the blood concentration profile in the first weeks of treatment ([@bib47]). The second was a three-compartment model with the absorption described by a transit compartment model fitted to plasma chloroquine concentrations from healthy adult volunteers who took oral single 620 mg base equivalent doses of chloroquine on two separate occasions with or without primaquine ([@bib34], a total of 640 concentration measurements: each volunteer was sampled 20 times at two separate dosing occasions; the model is not yet published). This model included allometric scaling as described above. Published estimates for the plasma to blood ratio vary considerably (reviewed in [@bib28]). We choose a scaling ratio of 4 as this resulted in equal median concentrations for both pharmacokinetic models and is approximately the median value from the review in [@bib28].

Five potential chloroquine COVID-19 adult treatment regimens, and one malaria treatment regimen were simulated:

1.  600 mg base, twice daily for 10 days with no loading dose was given, as trialled in Brazil ([@bib2]).

2.  620 mg base loading dose at 0 and 6 hr, followed by 310 mg base twice daily (starting at 12 hr) for a total of ten days (two loading doses and 20 maintenance doses). Except for the loading doses, this is equivalent to the regimen recommended by the Health Commission of Guangdong Province (Multicenter collaboration group of Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus pneumonia., 2020). In base equivalent, this is the regimen given in the UK RECOVERY trial (hydroxychloroquine) and the World Health Organization SOLIDARITY trial (hydroxychloroquine or chloroquine, depending on the country of patient enrolment).

3.  620 mg base loading dose on day 1 at 0 and 6 hr, followed by 310 mg base twice daily (starting at 12 hr) for a total of seven days (two loading doses and 14 maintenance doses).

4.  Weight-adjusted dosing regimen targeting loading doses at 0 and 6 hr of 10 mg base/kg, followed by maintenance doses of 5 mg/kg for a total of ten days (starting at 12 hr), approximated to the nearest 155 mg base whole tablets.

5.  Weight-adjusted dosing regimen targeting loading doses at 0 and 6 hr of 10 mg base/kg, followed by maintenance doses of 5 mg/kg for a total of seven days (starting at 12 hr), approximated to the nearest 155 mg base whole tablets.

6.  A 'flat' standard malaria dosing regimen of 620 mg base on days 1 and 2, followed by 310 mg base on day 3, for the same range of weights.

Regimens 1--3 and 6 are 'flat' dosing regimens (i.e. not weight-based). All regimens were simulated for weights ranging from 40 to 90 kg at intervals of 5 kg.

Concentration-dependent model of death in chloroquine self-poisoning {#s4-4}
--------------------------------------------------------------------

We compared the relationship between admission whole blood chloroquine + desethyl metabolite concentration and death using logistic regression (maximum likelihood fit) for data gathered retrospectively ($n = 91$, [@bib35]) and data collected prospectively ($n = 302$, [@bib35]; [@bib10]; [@bib11]; [@bib28]). The retrospective data gave substantially different results with much higher probabilities of death (approximately 60% versus 5% at 20 µmol/L, see Appendix 1). We therefore excluded the 91 retrospectively studied patients reported in Riou et al. but retained the 11 prospectively studied patients from that publication. This gave a total of 302 unique patient observations.

We modeled the probability of death as a function of the log whole blood peak chloroquine concentration (µmol/L) using Bayesian logistic regression. The peak concentration is considered a latent variable (unobserved) for patients whose blood chloroquine concentrations peaked before hospital admission or for patients who only had their whole blood concentration measured on admission ($n = 241$). The peak concentration is considered observed for those who had multiple concentration measurements and for whom the peak occurred after hospital admission ($n = 61$). The model does not attempt to estimate individual peak concentrations for the patients whose peak concentrations were unobserved, but rather an average difference δ, on the log scale, between peak and admission concentrations (this can be considered as a bias correction term). This assumes that the probability of death, conditional on the peak drug concentration, was the same for those whose blood concentrations peaked before and after hospital admission. This assumption is likely to be incorrect. Patients whose levels peaked after hospital admission would have received supportive hospital care more rapidly (relative to time of peak concentration) than those who peaked before admission. However, the extent of this bias is unmeasurable.

In addition, the model adjusted for differences in hospital treatment received between the three cohorts: cohort 1 was the 11 prospectively studied patients in [@bib35]; cohort 2 was the 247 patients studied in [@bib10]; [@bib11] (named herein 'the Clemessy cohort'); cohort 3 was the 44 patients studied in [@bib28]. Substantial differences in standard of care occurred between these three cohorts. For example, the use of emergency extracorporeal life support started in the early 2000s and is thought to reduce chloroquine self-poisoning mortality considerably ([@bib27]). The prior over the study specific intercept terms was a normal distribution with mean 0 and standard deviation 0.5. We note that the stan code uses the following convention: cohort 1 coded as 0; cohort 2 coded as 1; cohort 3 coded as 2; healthy volunteers coded as 3.

To model the relationship between whole blood chloroquine concentrations and a fatal outcome we use a correction factor γ to account for the desethyl metabolite included in the assay measurement. Between 1 and 6 hr post ingestion, the desethyl metabolite will account for approximately 30% of the total concentration measured ([@bib34]). The values of γ and ~δ~ are not directly identifiable from the data, but there are good a priori estimates for δ ([@bib34]). The data from the individuals whose levels peaked after hospital admission were used to construct an informative prior distribution for γ.

In summary, for individuals with an observed peak concentration measurement, the likelihood function given the outcome is Bernouilli with the parameter on the logit scale equal to $\alpha + {\beta{\log{({\gamma x})}}} + a_{cohort}$, where *x* is the observed concentration (assumed to be the peak concentration), α is the global intercept term, $a_{cohort}$ is the hospital cohort random intercept term, and β is the concentration-dependent effect (slope). For individuals who peaked before hospital admission, or who only had one concentration measurement, the likelihood is Bernouilli with parameter on the logit scale equal to $\alpha + {\beta{({{\log{({\gamma x})}} + \delta})}} + a_{cohort}$.

The Bayesian posterior distribution over the model parameters used informative prior distributions for all four parameters. For the intercept term α, this was a normal distribution with mean −15 (i.e. 1 in 10^7^ chance of dying at a whole blood concentration of 1µmol/L), and standard deviation 1; for the β coefficient on the log concentration, it was a normal distribution with mean 4 and standard deviation 1. The bias term δ was given an exponential prior with rate 8 (estimated from the 61 individuals whose levels peaked after hospital admission). The metabolite correction factor γ was given a normal prior with mean 0.7 and standard deviation 0.065 (the standard deviation was estimated from chloroquine and metabolite measurements in 107 malaria patients from [@bib9]).

Coupled pharmacokinetic and concentration-fatality model {#s4-5}
--------------------------------------------------------

For each chloroquine regimen and each weight category considered, we simulated 1000 pharmacokinetic profiles. The simulation was run from the time of the first dose until 7 hr after the last dose (7 hr will adequately capture the C~max~ value). Each simulated pharmacokinetic profile was summarised by the peak concentration denoted C~max~. The set of C~max~ values was then used to predict mean fatality ratios using the concentration-fatality model estimated from the chloroquine self-poisoning data (herein referred to as the pharmacodynamic model). We propagated uncertainty from the pharmacodynamic model by estimating desired quantities using 4000 random draws from the posterior distribution. For the estimation of mortality under the different regimens, we truncated the concentration-dependent mortality prediction at 1% (the concentration at which this truncation occurs will vary depending on the draw from the posterior distribution). This is because estimating mortality ratios below 1% is unreliable given a sample size of a few hundred and will be highly dependent on the prior distribution chosen and the parametric form of the concentration-fatality curve. For example, the posterior predictive model estimates a mortality of the order of 1 per 100,000 at 2µmol/L. This is approximately the background rate of sudden unexplained death in a young adult population ([@bib5]), therefore rendering the prediction essentially unverifiable (non-scientific).

Concentration-dependent model of electrocardiograph QRS widening {#s4-6}
----------------------------------------------------------------

We estimated the relationship between chloroquine concentrations and QRS interval duration by fitting a Bayesian sigmoid Emax model. The likelihood function of the regression model was specified as:$${QRS}_{i} \sim {Normal}\ \left( {E_{max} - \frac{E_{max} - E_{min}}{1 + e^{k({log}_{10}x_{i} - E_{50})}},\epsilon_{i}^{(j)}} \right),\ j = \{ 1,2,3\}$$where $\text{QRS}_{i}$ is the observed QRS duration and *x*~*i*~ is the chloroquine concentration for individual *i*. This concentration is simultaneously measured (plasma converted to whole blood) for the healthy volunteers, and is the admission chloroquine concentration (70% of measured whole blood concentration to remove the metabolite contribution) for the self-poisoning patients. The standard error ϵ is modeled separately for the self-poisoning patients and the healthy volunteers. This helps to adjust partially for the concentration-dependent heteroskedasticity in QRS values and the differences in measurement error between pooled datasets (manually read ECGs in the Clemessy cohort and greater difficulty in accurate interval measurement at the high concentrations seen in self-poisoning (cohorts 2 and 3) versus automated reading in the healthy volunteer data).

The data from the self-poisoning patients are considered independent and identically distributed conditional on the observed concentration and the study cohort. The prior for the error term $\epsilon_{i}^{(1)}$ for the Clemessy cohort was a normal distribution with mean 25 and standard deviation 5. The prior for the error term $\epsilon_{i}^{(2)}$ for cohort 3 was a normal distribution with mean 15 and standard deviation 5.

The data from the healthy volunteers are analyzed with a hierarchical error model (also known as a mixed effects model). We estimate an individual intercept term for each volunteer (the prior distribution over intercept terms was a normal with mean 0 and standard deviation $\sigma_{HV}$; the prior over $\sigma_{HV}$ was an exponential distribution with rate parameter 0.2 corresponding to a standard deviation of 5 msec in normal QRS values between individuals). The measurement error model, $\epsilon_{i}^{(3)}$, was then given a normal prior with mean 2 and standard deviation 1. The QRS interval data from the healthy volunteers measured in the absence of drug were used to estimate the mean increase in QRS at detectable drug levels (the difference between E~min~ and the mean QRS when no drug is detectable).

From a visual check of the raw QRS data (Appendix 5), the QRS values from the Clemessy series appear to be slightly biased downwards, and so we modeled this with an additional bias term (prior is a normal distribution with mean −20 and standard deviation 5). E~max~ is the maximum mean QRS duration (prior is a normal distribution with mean 180 and standard deviation 10); E~min~ is the minimum mean QRS duration (prior is a normal distribution with mean 90 and standard deviation 4); E~50~ is log~10~ chloroquine concentration that results in a mean QRS duration of half the maximal increase (prior is a normal distribution with mean 1.3 and standard deviation 1); the slope parameter *k* is modeled on the log scale (prior is a normal distribution with mean 1 and standard deviation 1). The prior distribution over the hierarchical intercept terms for the healthy volunteers was a normal distribution with mean 0 and standard deviation σ~*i*~ which was given an exponential prior with rate 0.2.

Statistical analysis {#s4-7}
--------------------

Both Bayesian regression models were fitted to data using *stan* ([@bib4]), implemented in *R*. Uncertainty around each fit was reported as centred 95% credible intervals. For each model 10^5^ posterior samples were drawn from eight independent chains, the first half were discarded for burn-in and second half thinned every 100 samples. This resulted in 4000 posterior samples used to characterise the posterior distributions. Mixing was assessed by agreement between chains and traceplots. Comparison of prior and posterior distributions are given in Appendix 2.

Code and data availability {#s4-8}
--------------------------

All code (including the NONMEM simulation scripts) and data can be found on github at <https://github.com/jwatowatson/Chloroquine-concentration-fatality> ([@bib46]; copy archived at [https://github.com/elifesciences-publications/Chloroquine-concentration-fatality)](https://github.com/elifesciences-publications/Chloroquine-concentration-fatality).
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Data availability {#s7}
=================

All data analysed during this study are included in the github repository linked in the manuscript (<https://github.com/jwatowatson/Chloroquine-concentration-fatality>; copy archived at <https://github.com/elifesciences-publications/Chloroquine-concentration-fatality>). All Figures can be generated from the scripts in this repository.

![Comparing the concentration fatality-curves obtained when using the retrospectively gathered data (blue dashed line, $n = 91$, [@bib35]) versus the prospectively gathered data (black solid line, $n = 302$, [@bib35]; [@bib10]; [@bib11]; [@bib28]).\
The parameters of the two logistic regression fits correspond to maximum likelihood estimates.](elife-58631-app1-fig1){#app1fig1}

![Comparison between prior distributions (thick red lines) and posterior distributions (shown as histograms) for the parameters of the concentration-fatality model.\
The top three histograms show the estimated intercept terms for the three cohorts (cohort 1: [@bib35]; cohort 2: [@bib10], [@bib11]; cohort 3: [@bib28]). α is overall intercept term; β: log-concentration coefficient; δ: bias term for patients whose peak concentration was not observed; γ: fraction of concentration that is due to chloroquine and not the metabolite. This shows that the data are informative with respect to the β coefficient on the log concentration. This is the desired behaviour given we know that chloroquine at low doses is very safe. See the meta-analysis of the related bisquinoline compound piperaquine showing that under normal dosing, the mortality is unlikely to be greater than the background mortality rate ([@bib5]).](elife-58631-app2-fig1){#app2fig1}

![Comparison between prior distributions (thick red lines) and posterior distributions (shown as histograms) for the population parameters of the concentration-QRS duration Emax sigmoid regression model.](elife-58631-app2-fig2){#app2fig2}

![Predicted C~max~ distributions for a 70 kg adult for the plasma pharmacokinetic model (black) and the whole blood pharmacokinetic model (red) under the six different regimens.\
The predicted plasma concentrations were scaled by four to produce approximate whole blood concentrations. The areas under all the curves are equal to 1, with the all y-axes given the same height in order to highlight differences in width of predicted distributions.](elife-58631-app3-fig1){#app3fig1}

![Pharmacokinetic-pharmacodynamic model of chloroquine induced mortality under the plasma pharmacokinetic model of chloroquine.\
Top: pooled whole blood chloroquine + desethylchloroquine concentrations from admission samples in prospectively studied self-poisoning patients ([@bib35]; [@bib10]; [@bib11]; [@bib28]). The data are shown as overlapping histograms for survivors (blue, $n = 269$) and fatal cases (red, $n = 33$). Bottom: Bayesian posterior distribution over the concentration-response curve (mean and 95% credible interval) describing the relationship between admission whole blood chloroquine concentrations (after adjustment for the deseythl metabolite) and death, with the chloroquine concentration shown on the log~10~ scale. The vertical lines show the upper 99 percentiles of the predicted C~max~ distribution in a 70 kg adult under the plasma pharmacokinetic model for the six regimens considered (yellow: 10 day regimen with maintenance dose of 310 mg; pink: 10 day regimen with maintenance dose of 600 mg; brown: 7 day regimen with maintenance dose of 310 mg; grey: malaria regimen). The vertical light pink shaded area shows the posterior credible interval over the concentrations associated with 1% mortality. This is the equivalent output of the whole blood model shown in [Figure 2](#fig2){ref-type="fig"}, main text.](elife-58631-app4-fig1){#app4fig1}

![The predicted risk of fatal toxicity across the six chloroquine regimens simulated under the plasma pharmacokinetic model.\
Panel A shows the simulated distribution of C~max~ values in a 70 kg adult for the six regimens considered. The vertical red shaded area shows the 95% credible interval for the 1% mortality threshold concentration. Panel B shows the probability that an individual will cross the 1% mortality threshold value as a function of body weight for the different regimens (log~10~ scale on the y-axis). Panel C shows the predicted mortality per thousand for the six regimens as a function of body weight.](elife-58631-app4-fig2){#app4fig2}

![Raw concentration-QRS interval scatter plot without any bias adjustment or truncation of the QRS data.\
To model the relationship between concentrations and QRS intervals we truncated the QRS values at 200 msec (durations longer than 200 msec are physiologically very unlikely) and estimated a bias term for the data from the Clemessy series ([@bib10]; [@bib11]).](elife-58631-app5-fig1){#app5fig1}

![Electrocardiograph showing marked intraventricular conduction delay (QRS widening) with moderate JT prolongation in a 28-year-old female who had taken 5 g of chloroquine.\
Her admission whole blood chloroquine + desethychloroquine concentration was 35.4 µmol/L but fortunately she survived.](elife-58631-app6-fig1){#app6fig1}
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In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.

**Acceptance summary:**

Your work provide useful insights regarding potential safety issues to be considered in studies investigating the role of chloroquine and hydroxychloroquine in several disease states, particularly COVID-19.

**Decision letter after peer review:**

Thank you for submitting your article \"Concentration-dependent mortality of chloroquine in overdose\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Matthias Barton, MD, as the Senior Editor. The following individuals involved in review of your submission have agreed to reveal their identity: Nick Holford (Reviewer \#1); Karen Barnes (Reviewer \#3).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

This paper describes a modelling and simulation project which utilises a mixture of data-sets to predict the likely concentrations (total blood) from the currently recommended hydroxychloroquine (HCQ) (chloroquine (CQ)) dose regimens for COVID-19.

Essential revisions:

The NONMEM simulation code could not be found in the list of contents of the GitHub site. When searching for NONMEM in the Rmd file it does not appear. Please provide full details on how to access the PK modelling used.

Subsection "Pharmacodynamic modelling": Please describe the model used to simulate the PK profile in order to obtain peak concentrations.

As not all regimens could be tested in the model, it would be highly informative to have the loading, maintenance and duration of dose used in the \~90 registered clinical trials summarised in a supplementary table. This would clarify how the wide range of chloroquine dosages currently being used relate to dosages modelled in terms of predicted exposure and mortality risk. This is needed to support the Impact statement that \"Most chloroquine regimens trialled for the treatment of COVID19 will not result in life-threatening cardiovascular toxicity\".

\[Editors\' note: further revisions were suggested prior to acceptance, as described below.\]

Thank you for submitting your article \"Concentration-dependent mortality of chloroquine in overdose\" for consideration by *eLife*. Your article has been reviewed by two peer reviewers, and the evaluation has been overseen by a Reviewing Editor and a Senior Editor.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Essential revisions:

-- Introduction: The term \"weak\" is used again but without an explanation of what it means. The authors should state as they have in the response to my original comment, that antiviral effects are expected to be small because predicted unbound concentrations of CQ in vivo are lower than those than the C50 reported for in vitro cell culture anti-viral effects.

-- You continue to describe volumes as enormous without any reference to support these assertions. As I have pointed out it is not possible to reliably estimate such large volumes and long terminal half lives. The volumes of distribution in the 2 models you have used for whole blood (Vcentral 468 L/52 kg and Vperipheral of 1600 L/52 kg) and for plasma (Vcentral 2020 L/61.9 kg, Vshallow 6740 L/61.9 kg and Vdeep 3270 L/61.9kg are not 200-300 L/kg as you state in your response. These commonly cited 100s of L/kg values in the literature has been uncritically repeated by others and you should not make the same mistake. You have 2 adequate PK models which you can use to give more reasonable estimates of volumes and terminal half-life.

-- Note that it is not helpful to standardize these 2 models to different weights (52 kg, 61.9 kg). The fit of the data is not affected by using a common standard weight e.g. 70 kg (1). Using a standard weight allows different studies to be compared much more easily (2).

-- Response to my comments about peak concentrations. It is still not clear to me how you claim to estimate peak concentrations using a latent variable. You say you did not a published PK model so what PK model did you use?

-- Please also answer my question about why you did not use the observed concentrations for a logistic regression or time to event analysis. That would avoid the problem of trying to predict a peak concentration.

-- The description of the two NM-TRAN code files refers to a QRS model but these files only describe CQ concentrations and not QRS. The descriptions of these files should be changed or provide files which include CQ and QRS code.

-- The comments for \$Σ in the two NM-TRAN code files should be corrected.

-- Hoglund_wholeblood_CQ_mod, Line 101 says simulation is without residual error but \$Σ is not zero. However, it is close to zero and thus the residual error will be small.

\$Σ 0.00001 ;Simulation without residual error.

-- Pukrittayakarnee_plasma_CQ.mod, Line 118 says simulation is without residual error but \$Σ is not zero (SD=0.64 mg/L) so there will be residual error in the predicted concentration. \$Σ 0.0806 ;Simulating without residual error.

10.7554/eLife.58631.sa2

Author response

> Essential revisions:
>
> The NONMEM simulation code could not be found in the list of contents of the GitHub site. When searching for NONMEM in the Rmd file it does not appear. Please provide full details on how to access the PK modelling used.

We apologize for this oversight! Both NONMEM simulation models (based on whole blood and plasma) are now in the github repository in the folder "NONMEM".

> Subsection "Pharmacodynamic modelling": Please describe the model used to simulate the PK profile in order to obtain peak concentrations.

This now reads:

"Two models were used for simulation in NONMEM (v.7.4.3, Icon Development Solution, Ellicott City, MD; the NONMEM simulation code is available online; see github repository link below). The first was a published two-compartment disposition model with a transit compartment absorption model using whole blood measurements from adult vivax malaria patients treated with a standard 25 mg base/kg regimen over three days \\citep{hoglund2016population} ($n = 75$, with over 1000 concentrations measurements). Allometric scaling of body weight, with the exponent fixed to 0.75 for clearance parameters and 1 for volume parameters, was added to the published model to predict concentrations at different body weights. The second was a three-compartment model with the absorption described by a transit compartment model fitted to plasma chloroquine concentrations from healthy adult volunteers who took single 600 mg base equivalent doses of chloroquine on two separate occasions with or without primaquine \\citep{pukrittayakamee2014pharmacokinetic} (\$n=16\$, not yet published). This model included allometric scaling."

> As not all regimens could be tested in the model, it would be highly informative to have the loading, maintenance and duration of dose used in the \~90 registered clinical trials summarised in a supplementary table. This would clarify how the wide range of chloroquine dosages currently being used relate to dosages modelled in terms of predicted exposure and mortality risk. This is needed to support the Impact statement that \"Most chloroquine regimens trialled for the treatment of COVID19 will not result in life-threatening cardiovascular toxicity\".

Thank you for this suggestion. We agree that this is an important exercise to support our conclusion. We obtained 77 results from [ClinicalTrials.gov](https://clinicaltrials.gov/) (as of 11 June 2020) when restricting to interventional trials that are currently recruiting participants in hospital. Of these, 55 were treatment trials for which we could determine the exact dosing and the duration. Figure 1 now shows the meta-data from these 55 trials (scatter plot of regimen duration versus total dose in base equivalent). We have simulated the highest currently recruiting chloroquine regimen (equal to that of the WHO SOLIDARITY trial). This useful exercise also highlighted one other trial that is administering potentially dangerous large doses and this prompted us to contact the investigators to warn them.

\[Editors\' note: further revisions were suggested prior to acceptance, as described below.\]

> Essential revisions:
>
> -- Introduction: The term \"weak\" is used again but without an explanation of what it means. The authors should state as they have in the response to my original comment, that antiviral effects are expected to be small because predicted unbound concentrations of CQ in vivo are lower than those than the C50 reported for in vitro cell culture anti-viral effects.

This paragraph now reads:

"Chloroquine and hydroxychloroquine are antivirals with a broad range of activities (including flaviviruses, retroviruses, and coronaviruses) (Savarino et al., 2003; Liu et al., 2020; Wang et al., 2020; Yao et al., 2020; Mégarbane and Scherrmann, 2020). Their antiviral activity against SARS-CoV2 is expected to be weak as predicted unbound concentrations of hydroxychloroquine and chloroquine in vivo with currently recommended doses are lower than the half-maximal effect concentrations reported in Vero cell cultures (White et al., 2020)."

> -- You continue to describe volumes as enormous without any reference to support these assertions. As I have pointed out it is not possible to reliably estimate such large volumes and long terminal half lives. The volumes of distribution in the 2 models you have used for whole blood (Vcentral 468 L/52 kg and Vperipheral of 1600 L/52 kg) and for plasma (Vcentral 2020 L/61.9 kg, Vshallow 6740 L/61.9 kg and Vdeep 3270 L/61.9kg are not 200-300 L/kg as you state in your response. These commonly cited 100s of L/kg values in the literature has been uncritically repeated by others and you should not make the same mistake. You have 2 adequate PK models which you can use to give more reasonable estimates of volumes and terminal half-life.

We do not want to hold the paper up with this semantic argument. We fully agree that it is not possible to estimate such large volumes and long terminal half lives reliably. We have pointed out that two compartment models are an oversimplification because they substantially underestimate the terminal elimination phase and therefore underestimate the total apparent volume of distribution. We have attenuated "enormous" to "very large", and added that the true values cannot be measured accurately which seems a reasonable deduction from the above and compromise with the reviewer.

> -- Note that it is not helpful to standardize these 2 models to different weights (52 kg, 61.9 kg). The fit of the data is not affected by using a common standard weight e.g. 70 kg (1). Using a standard weight allows different studies to be compared much more easily (2).

This has been changed. Both models now use a standard weight of 70 kg.

> -- Response to my comments about peak concentrations. It is still not clear to me how you claim to estimate peak concentrations using a latent variable. You say you did not a published PK model so what PK model did you use?

In the previous response we wrote: For these reasons, it is difficult to use a published PK model to model the data and the peak is instead defined as a latent variable, as this is a simpler framing of the problem. The observation is thus a noisy estimate (biased downwards) of the peak.

This could have been clearer. We meant that we did not use a standard compartmental pharmacokinetic model (i.e. the one used to predict peak concentrations). Instead, in the logistic regression, we frame the problem as a latent variable, and estimate a correction factor. We should have written down the exact formulation of the likelihood functions in the text. This has now been added in subsection "Concentration-dependent model of electrocardiograph QRS widening".

> -- Please also answer my question about why you did not use the observed concentrations for a logistic regression or time to event analysis. That would avoid the problem of trying to predict a peak concentration.

We do use the observed concentrations but with an additional correction factor. We apologise for the lack of clarity in the Materials and methods. We hope subsection "Concentration-dependent model of electrocardiograph QRS widening" with the exact formulation of the model now make the text easier to understand. The time of death was not recorded for the large majority of patients so we use the binary endpoint instead (died/survived).

> -- The description of the two NM-TRAN code files refers to a QRS model but these files only describe CQ concentrations and not QRS. The descriptions of these files should be changed or provide files which include CQ and QRS code.

I think this is a misunderstanding of how github displays information (we agree it is very confusing!). The description you are referring to shows the text from the last "commit" and "push". The last major change for the previous submission that was made was a change to the QRS model and also a very minor change to the NONMEM file. That's why the "commit" text has "re-run QRS model". This is like a note-to-self rather than a description of the file (this is what commit messages on github are designed to be).

> -- The comments for \$SIGMA in the two NM-TRAN code files should be corrected.

We have changedSIGMA values to 0.

> -- Hoglund_wholeblood_CQ_mod, Line 101 says simulation is without residual error but \$SIGMA is not zero. However, it is close to zero and thus the residual error will be small.
>
> \$SIGMA 0.00001 ;Simulation without residual error.

We were using the IPRED values as model output, so the value of SIGMA does not impact this and therefore the statement that simulation was done without residual error is correct. For clarity we have set SIGMA=0 in both files.

> -- Pukrittayakarnee_plasma_CQ.mod, Line 118 says simulation is without residual error but \$SIGMA is not zero (SD=0.64 mg/L) so there will be residual error in the predicted concentration. \$SIGMA 0.0806 ;Simulating without residual error.

Same as above.
